Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Towards Broadly Neutralizing Antibody InductionInduction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 VaccineesMichael Anthony Moody, David Easterhoff, Thaddeus C. Gurley, John F. Whitesides, Dawn J. Marshall, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Ryan Duffy, Shaunna Shen, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Robert J. O'Connell, Sandhya Vasan, Jean-Louis Excler, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, Donald Francis, Carter Lee, Thomas B. Kepler, S. Munir Alam, Guido Ferrari, David C. Montefiori, Hua-Xin Liao, Georgia D. Tomaras, and Barton F. HaynesMichael Anthony MoodyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, David EasterhoffDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Thaddeus C. GurleyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, John F. WhitesidesDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Dawn J. MarshallDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Andrew FoulgerDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Krissey E. LloydDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Robert ParksDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Justin PollaraDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Ryan DuffyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Shaunna ShenDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Jerome H. KimUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Nelson L. MichaelUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Merlin L. RobbUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Robert J. O'ConnellAFRIMS, Bangkok, ThailandSearch for more papers by this author, Sandhya VasanAFRIMS, Bangkok, ThailandSearch for more papers by this author, Jean-Louis ExclerUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Supachai Rerks-NgarmThai Ministry of Public Health, Nonthaburi, ThailandSearch for more papers by this author, Jaranit KaewkungwalMahidol University, Bangkok, ThailandSearch for more papers by this author, Punnee PitisuttithumMahidol University, Bangkok, ThailandSearch for more papers by this author, Sorachai NitayaphanAFRIMS, Bangkok, ThailandSearch for more papers by this author, Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Donald FrancisGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Carter LeeGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Thomas B. KeplerBoston University, Boston, MA, United StatesSearch for more papers by this author, S. Munir AlamDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Guido FerrariDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, David C. MontefioriDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Hua-Xin LiaoDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Georgia D. TomarasDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, and Barton F. HaynesDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5057a.abstractAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees." AIDS Research and Human Retroviruses, 30(S1), p. A36FiguresReferencesRelatedDetailsCited byThe Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States24 May 2017 | Vaccines, Vol. 5, No. 2 Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Michael Anthony Moody, David Easterhoff, Thaddeus C. Gurley, John F. Whitesides, Dawn J. Marshall, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Ryan Duffy, Shaunna Shen, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Robert J. O'Connell, Sandhya Vasan, Jean-Louis Excler, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, Donald Francis, Carter Lee, Thomas B. Kepler, S. Munir Alam, Guido Ferrari, David C. Montefiori, Hua-Xin Liao, Georgia D. Tomaras, and Barton F. Haynes.Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees.AIDS Research and Human Retroviruses.Oct 2014.A36-A36.http://doi.org/10.1089/aid.2014.5057a.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

Induction of Broadly Neutralizing Antibodies to Hiv-1 Via Dna Motif Immunization

Sequence Characteristics of Hiv-1 B' Envelope Proteins and Its Potential Correlation with Broadly Neutralizing Activity

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Broad HIV-1 Neutralizing Antibody Response Induced by Heterologous Gp140/gp145 DNA Prime-Vaccinia Boost Immunization

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

HIV Type 1 B′/C Recombinant (CRF07_BC) in Virologic Noncontrollers Elicits Neutralizing Antibodies Against Heterologous but Not Autologous Viruses

Combined Approach of Vaccine and Antiviral Drugs Can Achieve Better Protection in Nhp Model Against Heterologous Shiv Challenges

Cross-Subtype Antibody and Cellular Immune Responses Induced by A Polyvalent Dna Prime-Protein Boost Hiv-1 Vaccine in Healthy Human Volunteers

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer

Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.